Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA)

Cantor Fitzgerald restated their overweight rating on shares of Zura Bio (NASDAQ:ZURA) in a research report released on Thursday morning, Benzinga reports.

Several other research firms have also commented on ZURA. Piper Sandler initiated coverage on Zura Bio in a research report on Friday, May 3rd. They issued an overweight rating and a $26.00 price target for the company. Oppenheimer lifted their target price on Zura Bio from $16.00 to $21.00 and gave the stock an outperform rating in a report on Friday, May 10th.

Zura Bio Stock Performance

Shares of ZURA opened at $3.28 on Thursday. The company’s fifty day moving average is $3.59 and its 200 day moving average is $3.76. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $7.63.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, sell-side analysts anticipate that Zura Bio will post -0.53 earnings per share for the current year.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Forefront Analytics LLC boosted its holdings in Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the period. AQR Capital Management LLC bought a new stake in shares of Zura Bio during the second quarter worth $43,000. Armistice Capital LLC boosted its stake in shares of Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the period. Great Point Partners LLC boosted its stake in shares of Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares during the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.